超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

 EntreMed   
EntreMed, Inc. 是一家致力于開發 ENMD-2076 的臨床階段制藥公司。ENMD-2076 是用于治療癌癥的選擇性血管生成激酶抑制劑。ENMD-2076 目前正在進行一項多中心二期卵巢癌研究，并且已經完成了多個有關實體腫瘤、多發性骨髓瘤和白血病的一期研究

EntreMed, Inc. is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market. Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer. EntreMed, Inc. recently initiated a Phase 2 study of ENMD-2076 in triple-negative breast cancer.